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S U M M A R Y
Hepatitis C virus (HCV) infection is a never-ending public health problem. Many studies have
investigated the incidence of HCV infection among dialysis patients, but there have only been a few
epidemiological studies in renal conservative therapy. We studied 320 subjects with pre-dialysis chronic
kidney disease living in Sicily, Italy. The incidence of HCV infection was 6.25%. In Europe, incidence
ranges from 0.2% to 3.5%. It appears that the incidence of HCV infection is higher in the studied patient
population than in the population as a whole.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infection with the hepatitis C virus (HCV) is an unsolved public
health problem.1 HCV infects approximately 170 million people
worldwide. In Europe its incidence ranges from 0.2% to 3.5%
(Figure 1).2 HCV infection can detrimentally affect patients
throughout the spectrum of chronic kidney disease (CKD): it can
lead to cryoglobulinemic glomerulonephritis and it has a negative
effect on the survival of chronic dialysis patients, as well as renal
transplant patients.3,4 Also hepatitis C could be a risk factor for
pregression of CKD. Many studies have investigated the incidence
of HCV infection among chronic dialysis patients, but there have
only been a few epidemiological studies on its presence in pre-
dialysis patients.5–7 We investigated the incidence of HCV
infection among pre-dialysis CKD patients living in Sicily, Italy.
2. Materials and methods
From January to December 2009 we screened 547 patients later
sent to the Nephrology Department of the Civic Hospital in Palermo.
We excluded 224 subjects on maintenance dialysis, two HCV-
positive liver cirrhosis patients, and one HCV-positive and acute
renal failure subject. We selected 320 CKD patients on conservative* Corresponding author. Tel.: +393332318100; fax: +390916663454.
E-mail address: gioacchinolicavoli@libero.it (G. Li Cavoli).
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we tested for HCV antibodies using a chemiluminescent micropar-
ticle immunoassay (Architect Abbott), immunoblotting by INNOLIA,
viral detection by real-time PCR (COBAS TaqMan, Roche), and viral
genotype by INNO-LiPA 2.0. The results of hepatic and renal function
tests were recorded: aspartate aminotransferase (AST), alanine
aminotransferase (ALT), bilirubin, albumin, proteinuria, and creati-
nine clearance by modiﬁed diet in renal disease formula (MDRD).
3. Results
Among 320 CKD patients on conservative therapy, we identiﬁed
24 IgG HCV-positive subjects. Among these patients, four were
HCV-RNA-negative and 20 were HCV-RNA-positive. The incidence
of HCV infection was 6.25%. These patients showed a history of
blood transfusions and major surgeries. All subjects were hepatitis
B surface antigen (HBsAg)-negative; four patients were hepatitis B
surface antibody (HBsAb)- and/or hepatitis B core antibody
(HBcAb)-positive. We detected genotype 1b in 17 patients and
2a/2c in three patients. Hepatic function tests were unremarkable
(Table 1).
4. Discussion
Despite the screening of blood products, the incidence of HCV
infection in hemodialysis treatment patients is higher than that in
the general population: USA 7.4%, Japan 13.4%, Europe 11.5%, Italyses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Estimated current prevalence of HCV infection in the general population of the countries of Europe. (From Esteban JI, Sauleda S, Quer J. The changing epidemiology of
hepatitis C virus infection in Europe. J Hepatol 2008;48:148–62.).
Table 1
Characteristics of the 320 chronic kidney disease patients included in the study
HCV-positive, n = 20 (6.25%) HCV-negative, n = 300 (93.75%) p-Value
Male 13 (65%) 178 (59.3%) NSa
Female 7 (35%) 122 (40.7%)
Age, years 69.4  15 67.5  20 NSb
Transfusions and major surgery
Prior to 1992 5 (25%) 15 (5%) < 0.005
Post 1992 13 (65%) 31 (10.3%) NS
CKD stage
1 1 (5%) 9 (3%)
2 1 (5%) 32 (10.7%)
3 4 (20%) 76 (25.3%)
4 6 (30%) 75 (25%)
5 8 (40%) 108 (36%) NSc
Primary cause of nephropathy
Diabetes mellitus 4 (20%) 56 (18.7%) NS
Hypertensive disease 8 (40%) 97 (32.3%) NS
Glomerulonephritis 2 (10%) 46 (15.3%) NS
Tubulointerstitial diseases 4 (20%) 35 (11.7%) NS
Amyloidosis 1 (5%) 0 (0%) NS
Other 0 (0%) 34 (11.3%) NS
Undetermined 1 (5%) 32 (10.7%) NS
Genotype
1b 17 –
2a/2c 3 – –
Total bilirubin mg/dl 0.9  0.4 0.7  0.3 NSb
Albumin g/dl 3.1  0.6 3.3  0.8 NSb
AST U/l 21  8 18  7 NSb
ALT U/l 23  9 20  6 NSb
HCV, hepatitis C virus; NS, not signiﬁcant; CKD, chronic kidney disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Data are expressed as n (%) or mean  standard deviation; to evaluate differences in means and frequencies between the two groups Student’s t-test, Fisher’s exact test, Chi-square,
and Spearman’s rank correlations (rho) were used, where appropriate.
aChi-square; bStudent’s t-test; cSpearman’s rho = 0.035; dFisher’s exact test.
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University). In 2009 the incidence in Sicily was 10% (source:
Sicilian Hemodialysis Registry). Pre-dialysis CKD patients do not
share some of the risk factors found in chronic dialysis patients:
vascular cannulations and hemodialysis catheter use, graft and
arteriovenous ﬁstula creation and use, hemodialysis machines, and
person-to-person transmission through healthcare workers. There
has been no study on the incidence of HCV infection among the
people of Sicily, Italy. It is interesting to assess the natural history
of HCV infection in the renal population because of the chronic
immunosuppression of renal disease patients. It is useful to study
HCV infection in pre-dialysis CKD patients for the following
reasons: (1) HCV could accelerate the progression of CKD towards
the ﬁnal stages of renal disease; (2) dialysis patients with HCV
infection have an increased mortality risk compared with HCV-
negative dialysis patients; the increased risk of death in IgG HCV-
positive dialysis patients may be attributed at least in part to the
complications of chronic liver disease; (3) most CKD patients will
progress to end-stage renal disease.
In conclusion, we investigated the incidence of HCV infection in
CKD maintenance therapy patients. Our study showed 6.25% of
patients to be HCV-RNA-positive. We did not ﬁnd any differences
between these HCV-RNA-positive patients and those who were IgGHCV-negative with regard to Primitive cause of nephropathy, stage
of CKD, and biochemical parameters. We highlight the nosocomial
route as the source of HCV infection.
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